Document is current

Any future updates will be listed below

SCLC-Patienten mit hoher DLL3-Expression profitieren von Antikörper-Toxin-Konjugat

Crossref DOI link: https://doi.org/10.1007/s15033-018-1003-y

Published Online: 2018-08-28

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark